Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mavacamten
Pharma
Bristol Myers scoops up Asian rights to Camzyos for $350M
LianBio originally held the med's Asia commercialization rights under a 2020 collaboration with MyoKardia, which was later bought by Bristol Myers.
Zoey Becker
Oct 24, 2023 11:03am
BMS rolls unbranded campaigns for new heart drug Camzyos
May 10, 2022 4:44am
Bristol's heart med mavacamten passed muster at the FDA
Apr 29, 2022 3:33am
Bristol Myers notes 3 key launches to counter Revlimid losses
Jan 10, 2022 3:03pm
NBA rookie talks about his heart diagnosis in new BMS campaign
Nov 15, 2021 7:00am
